ERBB2 and breast carcinoma: Subsequently, we reduced CELF1 levels in luminal breast cancer cells and enhanced CELF1 expression in HER2-positive breast cancer cells using shRNA and the pcDNA3.1-CELF1 plasmid, respectively.